<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289431</url>
  </required_header>
  <id_info>
    <org_study_id>685</org_study_id>
    <nct_id>NCT01289431</nct_id>
  </id_info>
  <brief_title>Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis</brief_title>
  <official_title>Dose Ranging Study to Evaluate the Safety and Efficacy of Mapracorat Ophthalmic Formulation, in Subjects With Allergic Conjunctivitis Compared to Vehicle in a Conjunctival Allergen Challenge (CAC).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the dose response, and efficacy of Mapracorat&#xD;
      ophthalmic formulation compared to its vehicle for the prevention of symptoms and signs&#xD;
      associated with allergic conjunctivitis using a conjunctival allergen challenge (CAC) model.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Itching</measure>
    <time_frame>8 hours</time_frame>
    <description>Ocular itching was assessed by the participant on a 0-4 scale with half unit increments allowed. Lower scores indicate less ocular itching.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival Redness</measure>
    <time_frame>8 hours</time_frame>
    <description>Conjunctival redness was assessed by the Investigator on a 0-4 scale with half unit increments allowed. Lower scores indicate less conjunctival redness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ciliary Redness</measure>
    <time_frame>8 hours</time_frame>
    <description>The Investigator evaluated ciliary redness on a 0-4 scale with half unit increments allowed. A lower score is indicative of less ciliary redness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Episcleral Redness</measure>
    <time_frame>8 hours</time_frame>
    <description>Episcleral redness was evaluated by the Investigator using a 0-4 scale with half unit increments allowed. A lower score is indicative of less episcleral redness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">236</enrollment>
  <condition>Conjunctivitis, Allergic</condition>
  <arm_group>
    <arm_group_label>Mapracorat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mapracorat Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mapracorat</intervention_name>
    <description>administered daily to each eye for 2 weeks following allergen challenge using a CAC model</description>
    <arm_group_label>Mapracorat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>administered daily to each eye for 2 weeks following allergen challenge using a CAC model</description>
    <arm_group_label>Mapracorat Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  positive history of ocular allergies and a positive skin test reaction&#xD;
&#xD;
          -  positive bilateral CAC reaction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have known contraindications or sensitivities to the use of any of the study&#xD;
             medications(s) or their components.&#xD;
&#xD;
          -  have any ocular condition or significant illness that, in the opinion of the&#xD;
             investigator, could affect the subject's safety or trial parameters.&#xD;
&#xD;
          -  had ocular surgical intervention within three (3) months prior to Visit 1 or during&#xD;
             the study and/or a history of refractive surgery within the past 3 months;&#xD;
&#xD;
          -  a known history of retinal detachment, diabetic retinopathy, or active retinal&#xD;
             disease;&#xD;
&#xD;
          -  the presence of an active ocular infection or positive history of an ocular herpetic&#xD;
             infection at any visit.&#xD;
&#xD;
          -  use of any disallowed medications during the period indicated prior to Visit 1 and&#xD;
             during the study.&#xD;
&#xD;
          -  have planned surgery during the trial period or within 30 days after.&#xD;
&#xD;
          -  have an intraocular pressure that is less than 5 mmHg or greater than 22 mmHg or any&#xD;
             type of glaucoma at Visit 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rabia Ozden, OD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 1, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <results_first_submitted>August 18, 2020</results_first_submitted>
  <results_first_submitted_qc>September 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2020</results_first_posted>
  <disposition_first_submitted>February 28, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 3, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 7, 2012</disposition_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.3% Once a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="P2">
          <title>2% Once a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="P3">
          <title>3% Once a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="P4">
          <title>0.3% Twice a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="P5">
          <title>2% Twice a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="P6">
          <title>3% Twice a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="P7">
          <title>Vehicle</title>
          <description>Vehicle of BOL-303242-X dosed in the eye</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="34"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="33"/>
                <participants group_id="P7" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="31"/>
                <participants group_id="P7" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.3% Once a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="B2">
          <title>2% Once a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="B3">
          <title>3% Once a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="B4">
          <title>0.3% Twice a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="B5">
          <title>2% Twice a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="B6">
          <title>3% Twice a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="B7">
          <title>Vehicle</title>
          <description>Vehicle of BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="34"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="34"/>
            <count group_id="B6" value="33"/>
            <count group_id="B7" value="34"/>
            <count group_id="B8" value="236"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.6" spread="10.41"/>
                    <measurement group_id="B2" value="35.4" spread="13.62"/>
                    <measurement group_id="B3" value="37.7" spread="16.10"/>
                    <measurement group_id="B4" value="31.4" spread="11.46"/>
                    <measurement group_id="B5" value="36.0" spread="13.82"/>
                    <measurement group_id="B6" value="32.4" spread="12.03"/>
                    <measurement group_id="B7" value="35.1" spread="13.61"/>
                    <measurement group_id="B8" value="35.0" spread="13.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Itching</title>
        <description>Ocular itching was assessed by the participant on a 0-4 scale with half unit increments allowed. Lower scores indicate less ocular itching.</description>
        <time_frame>8 hours</time_frame>
        <population>Participants with results at the 8 hour timepoint are included, with no imputation for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O2">
            <title>2% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O3">
            <title>3% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O4">
            <title>0.3% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O5">
            <title>2% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O6">
            <title>3% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O7">
            <title>Vehicle</title>
            <description>Vehicle of BOL-303242-X dosed in the eye</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Itching</title>
          <description>Ocular itching was assessed by the participant on a 0-4 scale with half unit increments allowed. Lower scores indicate less ocular itching.</description>
          <population>Participants with results at the 8 hour timepoint are included, with no imputation for missing data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="1.212"/>
                    <measurement group_id="O2" value="1.34" spread="0.757"/>
                    <measurement group_id="O3" value="2.11" spread="1.196"/>
                    <measurement group_id="O4" value="2.06" spread="0.880"/>
                    <measurement group_id="O5" value="1.65" spread="0.804"/>
                    <measurement group_id="O6" value="1.58" spread="0.842"/>
                    <measurement group_id="O7" value="2.28" spread="0.985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Conjunctival Redness</title>
        <description>Conjunctival redness was assessed by the Investigator on a 0-4 scale with half unit increments allowed. Lower scores indicate less conjunctival redness.</description>
        <time_frame>8 hours</time_frame>
        <population>Participants with results at the 8 hour timepoint are included, with no imputation for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O2">
            <title>2% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O3">
            <title>3% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O4">
            <title>0.3% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O5">
            <title>2% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O6">
            <title>3% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O7">
            <title>Vehicle</title>
            <description>Vehicle of BOL-303242-X dosed in the eye</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Redness</title>
          <description>Conjunctival redness was assessed by the Investigator on a 0-4 scale with half unit increments allowed. Lower scores indicate less conjunctival redness.</description>
          <population>Participants with results at the 8 hour timepoint are included, with no imputation for missing data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="0.757"/>
                    <measurement group_id="O2" value="1.56" spread="0.723"/>
                    <measurement group_id="O3" value="2.01" spread="0.791"/>
                    <measurement group_id="O4" value="1.82" spread="0.779"/>
                    <measurement group_id="O5" value="1.72" spread="0.828"/>
                    <measurement group_id="O6" value="1.81" spread="0.757"/>
                    <measurement group_id="O7" value="2.14" spread="0.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ciliary Redness</title>
        <description>The Investigator evaluated ciliary redness on a 0-4 scale with half unit increments allowed. A lower score is indicative of less ciliary redness.</description>
        <time_frame>8 hours</time_frame>
        <population>Participants with results at the 8 hour timepoint are included, with no imputation for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O2">
            <title>2% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O3">
            <title>3% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O4">
            <title>0.3% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O5">
            <title>2% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O6">
            <title>3% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O7">
            <title>Vehicle</title>
            <description>Vehicle of BOL-303242-X dosed in the eye</description>
          </group>
        </group_list>
        <measure>
          <title>Ciliary Redness</title>
          <description>The Investigator evaluated ciliary redness on a 0-4 scale with half unit increments allowed. A lower score is indicative of less ciliary redness.</description>
          <population>Participants with results at the 8 hour timepoint are included, with no imputation for missing data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.903"/>
                    <measurement group_id="O2" value="1.39" spread="0.860"/>
                    <measurement group_id="O3" value="1.89" spread="0.875"/>
                    <measurement group_id="O4" value="1.60" spread="0.850"/>
                    <measurement group_id="O5" value="1.58" spread="0.915"/>
                    <measurement group_id="O6" value="1.65" spread="0.751"/>
                    <measurement group_id="O7" value="2.02" spread="0.780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Episcleral Redness</title>
        <description>Episcleral redness was evaluated by the Investigator using a 0-4 scale with half unit increments allowed. A lower score is indicative of less episcleral redness.</description>
        <time_frame>8 hours</time_frame>
        <population>Participants with results at the 8 hour timepoint are included, with no imputation for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.3% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O2">
            <title>2% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O3">
            <title>3% Once a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O4">
            <title>0.3% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O5">
            <title>2% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O6">
            <title>3% Twice a Day</title>
            <description>BOL-303242-X dosed in the eye</description>
          </group>
          <group group_id="O7">
            <title>Vehicle</title>
            <description>Vehicle of BOL-303242-X dosed in the eye</description>
          </group>
        </group_list>
        <measure>
          <title>Episcleral Redness</title>
          <description>Episcleral redness was evaluated by the Investigator using a 0-4 scale with half unit increments allowed. A lower score is indicative of less episcleral redness.</description>
          <population>Participants with results at the 8 hour timepoint are included, with no imputation for missing data.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="31"/>
                <count group_id="O7" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.739"/>
                    <measurement group_id="O2" value="1.56" spread="0.735"/>
                    <measurement group_id="O3" value="2.07" spread="0.763"/>
                    <measurement group_id="O4" value="1.85" spread="0.805"/>
                    <measurement group_id="O5" value="1.79" spread="0.868"/>
                    <measurement group_id="O6" value="1.97" spread="0.772"/>
                    <measurement group_id="O7" value="2.25" spread="0.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>0.3% Once a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="E2">
          <title>2% Once a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="E3">
          <title>3% Once a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="E4">
          <title>0.3% Twice a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="E5">
          <title>2% Twice a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="E6">
          <title>3% Twice a Day</title>
          <description>BOL-303242-X dosed in the eye</description>
        </group>
        <group group_id="E7">
          <title>Vehicle</title>
          <description>Vehicle of BOL-303242-X dosed in the eye</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site abnormal sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Instillation site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Contact sponsor directly for details.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Bausch Health</organization>
      <email>susan.harris@bauschhealth.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

